Healing peptide blend

GLOW

GLOW is a pre-mixed vial of BPC-157, TB-500 and GHK-Cu, and no study of the blend itself was identified; the app lists a half-life of about 3 hours.

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

GLOW after one dose: 50% at ~3 h, 25% at 6 h, 12.5% at 9 h.

Drawn from the half-life in the app's model, ~3 h. The model's figures

GLOW is listed in the app as a blend of three peptides: BPC-157 10 mg, TB-500 10 mg and GHK-Cu 50 mg, 70 mg in total per vial. No study of the blend was identified in PubMed or ClinicalTrials.gov on 16 November 2026. No DailyMed label was identified on the same date in searches for "BPC-157", "GHK-Cu copper tripeptide" or "thymosin beta-4".

The evidence that exists is for the components, mostly one at a time. Tewari and colleagues, American Journal of Sports Medicine, 2026, scoped the musculoskeletal literature on six peptides that include BPC-157, thymosin beta-4 or TB-500, and GHK-Cu, and report that "Overall, 67% of identified publications utilized preclinical animal models".2 They add that "Human clinical studies were limited to a handful of investigations, most lacking robust controls or rigorous study designs".2 Mendias and Awan, Sports Medicine, 2026, write that "a parallel "gray market" of unapproved compounds has emerged" alongside approved peptide drugs, and their review lists BPC-157, GHK-Cu and TB-500 among the peptides it covers.3 The app grades the evidence for GLOW as emerging.

What the three components are

Table 1.1Overview3 rows
ComponentPer vial (the app's figure)What the sources describe
BPC-15710 mgA "synthetic pentadecapeptide" in one systematic review and "a naturally occurring gastric peptide" in another; Poolton and colleagues identified three human studies (n=30) rated very low certainty4,5
TB-50010 mg"a distinct seven amino-acid fragment of TB-4" according to Tham and colleagues, who also report no controlled human orthopaedic efficacy evidence6
GHK-Cu50 mgGHK is a tripeptide present in human plasma, saliva and urine that declines with age; a 2026 systematic review calls the human literature "thin and fragmented"7,8

The mechanism descriptions in the sources come from animal, laboratory or review-level work on single components, and none of the sources read describes a mechanism for the three-peptide blend. Vasireddi and colleagues, HSS Journal, 2025, reviewed 36 studies of BPC-157 (35 preclinical, 1 clinical) and write that "The studies suggest that BPC-157 enhances growth hormone receptor expression and several pathways involved in cell growth and angiogenesis, while reducing inflammatory cytokines".5 Tham and colleagues, Journal of the American Academy of Orthopaedic Surgeons, 2026, describe TB-500 as "a distinct seven amino-acid fragment of TB-4" that is "frequently conflated with full-length TB-4 despite the absence of validated biologic or clinical equivalence".6 Esposito and colleagues, Doping Control Laboratory at Ghent University, Drug Testing and Analysis, 2012, report "the detection and the identification of the N-terminal acetylated 17-23 fragment of human thymosin beta 4 (Ac-LKKTETQ) in TB-500" by mass spectrometry.9 The rat study described below calls TB-500 "synthetic thymosin beta-4", so the sources describe it in two ways.10 Pickart and colleagues, who are affiliated with Skin Biology, write in BioMed Research International in 2015 that "It is proposed that GHK functions as a complex with copper 2+".7 The same review states that GHK "accelerates wound-healing of the skin, hair follicles, gastrointestinal tract, boney tissue, and foot pads of dogs" and "induces systemic wound healing in rats, mice, and pigs".7

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~3 h
Bioavailability
95%
Typical dose
3.5–10 mg/day
Route
SubQ
Time to peak
~0.5 h

The second column holds the app's own figures, shown beside what the sources report for the blend or, where none is reported, for a component.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-life~3 hNone reported for the blend; for BPC-157 alone, Vasireddi and colleagues give a half-life "of less than 30 minutes", reported after single and repeat intramuscular and intravenous dose administration, with no subcutaneous half-life in the text read5
Bioavailability95% (SubQ)None of the sources read reports a bioavailability for the blend or a component by subcutaneous injection; Tham and colleagues state that "Validated dosing, pharmacokinetic, and long-term safety data are lacking"6
Time to peak~0.5 hNone reported in the sources read
RouteSubQHuman work on BPC-157 in the sources used intra-articular, intravesical and intravenous routes4 and oral tablets in a registered phase 1 trial11; two registered trials list subcutaneous BPC-157 once daily12,13
Endogenous GHK in plasmaNot an app figure"about 200 ng/mL" at age 20, falling to "80 ng/mL by age 60" (Pickart and colleagues, 2015)7

The BPC-157 half-life is for one component, so it is not a half-life for the blend, and it differs from the app's figure of about 3 hours. The registry entry for a phase 1 trial of oral BPC-157 in healthy volunteers (PharmaCotherapia d.o.o.) lists "Elimination half life" among its secondary outcomes, with a status of "UNKNOWN".11

4

Human studies

No controlled study of GLOW in people was identified, so everything in the table below concerns one component, and a component's result is not a result for the blend.

Table 4.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
Poolton and colleagues, Acta Orthopaedica Belgica 20264PROSPERO-registered systematic review; Embase, PubMed, Cochrane Library and ClinicalTrials.gov searched to 1 June 2026Three BPC-157 studies, n=30: knee pain (n=16), interstitial cystitis (n=12), intravenous safety (n=2)Intra-articular, intravesical and intravenous; doses and lengths not stated in the record readSymptom improvement in most participants without treatment-related adverse events; poor methodological quality; certainty very low
Vasireddi and colleagues, HSS Journal 20255Systematic review to 3 June 2024; 36 studies, 35 preclinical and 1 clinicalThe clinical study: retrospective, 12 patients with unspecified chronic knee painBPC-157 alone, 2 cc of 2000 mcg/mL solution, intra-articular; length not stated in the text read7 of 12 reported subjective improvement for more than 6 months; "No clinical safety data were found."
Miller and colleagues, Archives of Facial Plastic Surgery 200614Randomized study of skin care regimens with or without GHK-Cu13 patients completed it after circumoral CO2 laser resurfacingTopical GHK-Cu skin care products; evaluated to 12 weeksNo significant difference between groups for erythema resolution or for wrinkles and overall skin quality on objective evaluation; the questionnaire showed higher overall skin quality improvement with GHK-Cu (P = .04)
PharmaCotherapia d.o.o., NCT02637284, registered 201511Phase 1, randomized, placebo-controlled pilot of oral BPC-157 (PCO-02) in healthy volunteers; status unknown42 planned, healthy volunteers aged 18 to 351 mg tablets: single doses of 1, 3 or 6 tablets, then 3 tablets three times daily for 2 weeksResults not stated in the entry read; primary outcome adverse events
Hudson Biotech, NCT07437547, registered 202612Phase 2, randomized, double-blind, placebo-controlled; recruiting120 planned; acute grade II hamstring strainSubcutaneous BPC 157 or placebo once daily for 14 daysNo results; recruiting
University of Arkansas, NCT07803250, registered 202613Phase 1, randomized, quadruple-masked pilot of BPC-157 versus a sham comparator arm described as normal saline injection, after rotator cuff repair; not yet recruiting30 planned in the enrollment field (the summary text says twenty)Subcutaneous once daily for 90 daysNo results; not yet recruiting

Deeper analysis: human evidence for BPC-157 in two systematic reviews

Poolton and colleagues, Acta Orthopaedica Belgica, 2026, included three studies with 30 people in all, and the authors judged them "to be of poor methodological quality".4 They used the National Institutes of Health tool for before-after studies with no control group and the GRADE framework, and rated overall certainty very low "due to serious risk of bias, indirectness and imprecision".4 Their conclusion is against clinical use of BPC-157 in humans outside "ethically approved, regulated, high-quality clinical trials".4 The PubMed record read for this review contains no funding statement or author disclosures, so its funder and the authors' ties to any sponsor are not stated in the text read. Vasireddi and colleagues, HSS Journal, 2025, searched PubMed, Cochrane and Embase from inception to June 3, 2024, and identified 544 articles.5 Their single clinical study was retrospective, and they report that "Out of 12 patients, 7 reported subjective improvement in symptoms for more than 6 months".5 They state that "No study assessed the safety or adverse events of BPC-157 in humans".5 The two reviews differ in search dates (June 2024 and June 2026) and in how many people they attribute to the intra-articular knee-pain work (12 in one, 16 in the other), and the text read does not reconcile these counts.4,5 Two other 2026 reviews describe the human musculoskeletal evidence as "one small retrospective uncontrolled case series without validated outcome measures" (Tham and colleagues) and "A single human case series" with "significant methodological flaws and a lack of controls" (Mayfield and colleagues, American Journal of Sports Medicine).6,1 Vasireddi and colleagues name their own limitations: "The heterogeneity in study design, objectives, and outcome measures restricted our ability to conduct a quantitative meta-analysis".5 They report that the authors "received no financial support for the research, authorship, and/or publication of this article", and one author declares a relationship with Stryker, others with Smith & Nephew, Arthrex and Mitek.5

Deeper analysis: GHK-Cu skin care after CO2 laser resurfacing

Miller and colleagues, Facial Aesthetic Concepts, San Clemente, reported a randomized study in Archives of Facial Plastic Surgery in 2006 of posttreatment skin regimens "with or without GHK-Cu" after circumoral CO2 laser resurfacing.14 The products were topical skin care products, not injections.14 Thirteen patients completed the study.14 Erythema resolution was assessed with computer software and blinded evaluators, which "found no statistically significant differences between groups for earlier resolution of erythema".14 The results section states that "All the patients experienced significant improvement in wrinkles and overall skin quality, but no differences were found between groups", while the conclusions state that "Objective evaluation found no significant improvement in wrinkles or overall skin quality".14 On a validated questionnaire, overall skin quality improved more with GHK-Cu (P = .04), and the authors write that "patient satisfaction was significantly higher for those who used GHK-Cu skin care products".14 The PubMed record read lists the publication type "Research Support, Non-U.S. Gov't" and gives no funder name, no maker of the products and no author statement on ties to a sponsor.14 Adverse events and discontinuations are not reported in the record read, and the number randomized is not stated there.14

Deeper analysis: BPC-157 with TB-500 in rat Achilles tendon repair

Biçer and colleagues, Bağcılar Training and Research Hospital in Istanbul, reported in Joint Diseases and Related Surgery in 2026 a study of BPC-157 and TB-500 given together and separately, and it was in rats, not people.10 Thirty-two male Sprague-Dawley rats underwent standardized Achilles tendon transection and repair and were randomly assigned to four groups of eight: control, BPC-157 (10 µg/kg/day), TB-500 (60 µg/kg/day), and combined BPC-157 + TB-500.10 Treatments "were administered intraperitoneally for four weeks postoperatively".10 GHK-Cu was not part of the study.10 Maximum load to failure was higher in the BPC-157 and TB-500 groups than in controls, "reaching statistical significance in the TB-500 group".10 The authors report "significantly lower total Bonar scores in the TB-500 group (p = 0.016) and significantly lower total Movin scores in the TB-500 and BPC + TB groups (p = 0.017 and p = 0.040, respectively) relative to controls".10 Among secondary results, "The BPC-157 group showed numerically lower scores without reaching statistical significance for total scores", and immunohistochemistry showed "no significant differences in collagen type I expression among groups" while "collagen type III expression differed significantly".10 They report that "Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone".10 The authors call it "this exploratory rat model study", describe the results as "preliminary findings", and say they need "dose-optimization and longer-term studies".10 They suggest the absence of additive effects "may reflect convergence on shared downstream pathways", a hypothesis that "requires further experimental confirmation".10 The PubMed record read gives no funding statement and no author disclosures, and it does not mention adverse events or deaths among the 32 rats.10

Deeper analysis: GHK-Cu in a rat model of ACL reconstruction

Fu and colleagues, Chinese University of Hong Kong, reported in the Journal of Orthopaedic Research in 2015 that 72 rats with unilateral anterior cruciate ligament reconstruction "were randomized to saline, 0.3 or 3 mg/ml GHK-Cu groups (n = 24)".15 Intra-articular injections "were given from week 2, once a week, for 4 weeks".15 At 6 weeks the GHK-Cu groups had "a smaller side-to-side difference in knee laxity as compared to the saline group (p = 0.009)", with no significant difference at 12 weeks.15 The 0.3 mg/ml group had higher graft stiffness at 6 weeks (p = 0.026), but "there was no significant difference in ultimate load, gait parameters, and histological scores among treatment groups".15 The authors conclude that "the beneficial effects could not last as treatment discontinued".15 The record lists the publication type "Research Support, Non-U.S. Gov't" and gives no funder name, no author disclosure and no adverse event data.15

Deeper analysis: who wrote the GHK-Cu literature

Najafi and colleagues, Archives of Internal Medicine Research, 2026, write that "the clinical literature in humans remains thin and fragmented: most randomized trials are small, conducted on facial cosmetic creams, and rarely paired with delivery technologies capable of reliably crossing the stratum corneum".8 In a section headed authorship and conflict of interest, Najafi and colleagues write that "Approximately 35% of the GHK-Cu primary literature in the inclusion window includes Loren Pickart or Anna Margolina" of Skin Biology, and that "Pickart was the original isolator of the peptide and held commercial interests in the field for decades"; their own competing interests statement says "All authors have read the manuscript and declare no conflict of interest", and their funding statement lists an NIH grant supporting one author.8 They add that "the concentration of authorship in a small number of investigators limits the independence of the evidence base".8 Pickart's own 2015 review declares "no conflict of interests" while listing a Skin Biology affiliation, and it states that "The molecule is very safe and no issues have ever arisen during its use as a skin cosmetic or in human wound healing studies".7

5

Doses reported in studies and on labels

No DailyMed label was identified on 16 November 2026 in searches for BPC-157, GHK-Cu copper tripeptide or thymosin beta-4, and no study of the blend was identified, so no dose of the blend is reported by a label or a trial. The table lists doses that sources report for single components, with the species and route; they are not doses of the blend.

Table 5.1Doses reported in studies and on labels5 rows
SettingComponent and doseRoute and lengthReference
Human, retrospective knee-pain study (12 patients, as summarized by a review)BPC-157 alone, 2 cc of 2000 mcg/mL solutionIntra-articular; length not stated in the text readVasireddi and colleagues 20255
Human, registered phase 1 in healthy volunteers, 42 plannedBPC-157 1 mg tablets: 1, 3 or 6 tablets once, then 3 tablets three times dailyOral; 2 weeks for the repeated scheduleNCT0263728411
Rats, Achilles tendon repair, 8 per groupBPC-157 10 µg/kg/day, TB-500 60 µg/kg/day, or bothIntraperitoneal; four weeksBiçer and colleagues 202610
Rats, ACL reconstruction, 24 per groupGHK-Cu 0.3 or 3 mg/ml versus salineIntra-articular, once a week for 4 weeks from week 2Fu and colleagues 201515
Authors' estimate for GHK in humans, not a trial dose"about 100–200 mgs of GHK"Based on the authors' own injection studies in animals, as they describe themPickart and colleagues 20157

The app's typical dose for GLOW is 3.5–10 mg/day, and none of the sources read reports a dose of the blend in people. Mayfield and colleagues conclude that "information regarding the indications, dosing, frequency, and duration of treatment remains unknown" for the injectable peptides they reviewed, which include all three components.1

No safety study of the blend was identified in PubMed or ClinicalTrials.gov on 16 November 2026. Poolton and colleagues report that all three human BPC-157 studies "reported symptom improvement in most participants without treatment-related adverse events", and they rated the studies poor in methodological quality and the certainty of evidence very low.4 Vasireddi and colleagues, whose search ended in June 2024, write that "No clinical safety data were found".5 In animal and in vitro models, they report that three studies "reported no acute toxicity across several organ systems", and that "No study assessed adverse events beyond 6 weeks following single or repeat administration of BPC-157 in animal models".5 For GHK-Cu, the safety statements in the sources read are Pickart and colleagues' own statement, from authors affiliated with Skin Biology, that "no issues have ever arisen during its use as a skin cosmetic or in human wound healing studies", and Najafi and colleagues' statement that "the safety signal from existing GHK-Cu use is strongly favorable"; neither source reports adverse event counts.7,8 Tham and colleagues write that commercial products "raise concerns regarding identity, purity, concentration, sterility, and manufacturing consistency".6 Mendias and Awan write that "rigorous human safety data are scarce, and there is potential for serious harm to patients" for many unapproved peptides.3

Tham and colleagues write that for BPC-157, thymosin beta-4 and TB-500, "None of these agents has an FDA-approved musculoskeletal indication, validated orthopaedic treatment protocol, or controlled human orthopaedic efficacy evidence".6 That review does not cover GHK-Cu.6 Vasireddi and colleagues list BPC-157 under "Category 2: Bulk drug substance that raises significant safety concerns" in their table of the FDA's stance.5 Najafi and colleagues state that GHK-Cu has had "FDA review with Category 2 restriction on injectable compounding as of 2023".8

The WADA 2026 Prohibited List names BPC-157 in section S0, non-approved substances, which is "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)".16 The same list names "Thymosin-ß4 and its derivatives e.g. TB-500" in section S2.3, growth factors and growth factor modulators.16 A text search of the 2026 list document for "GHK" and for "copper" returned no match, so GHK-Cu is not named in the text read. The list does not name GLOW as a product. A World Rugby news item reports that WADA's 2027 List was approved by its Executive Committee "during its meeting on 10 September 2026" and "enters into force on 1 January 2027", with further examples or clarifications added to class S0.17 The 2027 list text itself was not read, so its entries for these components are not described here. Mayfield and colleagues state that TB-4 and TB-500 "remain banned substances in sports", and Vasireddi and colleagues describe BPC-157 as having "its use being banned in professional sports".1,5

How the three-peptide blend is absorbed, cleared and tolerated is not reported in the sources read, because no study of the blend was identified. The app's half-life of about 3 hours, bioavailability of 95% and time to peak of about 0.5 hours have no matching figure in the sources read, apart from the BPC-157 half-life of less than 30 minutes. Whether BPC-157 and TB-500 add to each other is tested in one exploratory rat study, in which the combination "did not confer additional benefits compared to either agent alone"; whether GHK-Cu changes that is not reported.10 One review identified three BPC-157 studies (n=30) judged to be of poor methodological quality; Najafi and colleagues describe most GHK-Cu randomized trials as small and conducted on facial cosmetic creams; and Tham and colleagues report no controlled human orthopaedic efficacy evidence for BPC-157, thymosin beta-4 or TB-500.4,8,6 Mayfield and colleagues write that "significant research regarding the safety and efficacy of these therapeutic methods is required before definitive recommendations can be made to patients".1 Results for one component are not results for the blend.

What is in GLOW?

GLOW is listed in the app as a blend of BPC-157 10 mg, TB-500 10 mg and GHK-Cu 50 mg, 70 mg per vial.

What is the half-life of GLOW?

The sources read report no half-life for the blend, and the app lists about 3 hours. For BPC-157 alone, a systematic review gives a half-life of less than 30 minutes after single and repeat intramuscular and intravenous dose administration, which differs from the app's figure of about 3 hours.5

Has GLOW been studied in people?

No study of GLOW in people was identified in PubMed or ClinicalTrials.gov on 16 November 2026. Poolton and colleagues identified three BPC-157 studies (n=30) judged to be of poor methodological quality, with very low certainty of evidence.4

Is GLOW banned by WADA?

Two of GLOW's three components appear on the WADA 2026 Prohibited List: BPC-157 in S0 and TB-500 as a derivative of thymosin-ß4 in S2.3.16 GHK-Cu is not named in the 2026 list text, and the list does not name GLOW as a product.16 A 2027 list takes effect on 1 January 2027, and its text was not read.17

Is GLOW approved by the FDA?

No DailyMed label was identified on 16 November 2026 in searches for BPC-157, GHK-Cu copper tripeptide or thymosin beta-4. Tham and colleagues state that none of BPC-157, thymosin beta-4 or TB-500 has an FDA-approved musculoskeletal indication, and that review does not cover GHK-Cu.6

Do BPC-157 and TB-500 work better together?

One exploratory study in 32 rats with a repaired Achilles tendon reported that "Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone".10 No study of the combination in people was identified.10

What is the half-life of BPC-157?

A systematic review reports a BPC-157 half-life of less than 30 minutes after single and repeat intramuscular and intravenous dose administration.5 A registered phase 1 trial of oral BPC-157 lists half-life as a secondary outcome, and its status is unknown.11

Is there human evidence for GHK-Cu?

Najafi and colleagues write that the human clinical literature on GHK-Cu "remains thin and fragmented", with most randomized trials small and conducted on facial cosmetic creams.8 One randomized study of GHK-Cu skin care products after CO2 laser resurfacing had 13 patients complete it and showed no significant difference in erythema resolution between groups, while a questionnaire showed a significant difference in overall skin quality improvement for patients using GHK-Cu (P = .04).14

What is TB-500?

Tham and colleagues describe TB-500 as "a distinct seven amino-acid fragment of TB-4" that is "frequently conflated with full-length TB-4".6 Esposito and colleagues identified the N-terminal acetylated 17-23 fragment of human thymosin beta 4 (Ac-LKKTETQ) in a formulation called TB-500.9

11

References

  1. Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med 2026. PMID 41476424
  2. Tewari K, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med 2026. PMID 42578445
  3. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med 2026. PMID 41966639
  4. Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg 2026. PMID 42885452
  5. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025. PMID 40756949
  6. Tham A, et al. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. J Am Acad Orthop Surg 2026. PMID 42937313
  7. Pickart L, et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015. PMID 26236730
  8. Najafi N, et al. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res 2026. PMID 42787770
  9. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal 2012. PMID 22962027
  10. Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg 2026. PMID 42542926
  11. PharmaCotherapia d.o.o. PCO-02 - Safety and Pharmacokinetics Trial. ClinicalTrials.gov NCT02637284. NCT02637284
  12. Hudson Biotech. BPC 157 for Acute Hamstring Muscle Strain Repair. ClinicalTrials.gov NCT07437547. NCT07437547
  13. University of Arkansas. Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery. ClinicalTrials.gov NCT07803250. NCT07803250
  14. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006. PMID 16847171
  15. Fu SC, et al. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res 2015. PMID 25731775
  16. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
  17. World Rugby. WADA publishes 2027 Prohibited List. Keep Rugby Clean, 2026. World Rugby news item